Rigel Pharmaceuticals (RIGL) Non-Current Assets (2010 - 2026)

Rigel Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $270.6 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 820.06% year-over-year to $270.6 million in Q1 2026; TTM through Mar 2026 was $603.0 million, a 382.68% increase from a year earlier, with the FY2025 full-year figure at $273.4 million, up 847.0% from the prior year.
• Non-Current Assets fell to $270.6 million in Q1 2026 per RIGL's latest filing, from $273.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $273.4 million in Q4 2025 and bottomed at $5.2 million in Q3 2022.
• The 5-year median for Non-Current Assets is $27.6 million (2025), against an average of $51.4 million.
• Across the five-year window, Non-Current Assets tumbled 66.47% in 2022 and jumped 847.0% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $18.4 million in 2022, then declined by 2.27% to $18.0 million in 2023, then surged by 60.77% to $28.9 million in 2024, then soared by 847.0% to $273.4 million in 2025, then dropped by 1.04% to $270.6 million in 2026.
• Per Business Quant, the three latest RIGL Non-Current Assets figures stand at $270.6 million (Q1 2026), $273.4 million (Q4 2025), and $27.6 million (Q3 2025).